Skip navigation

Oncology profiles

 

ABLE Biosciences

08 December 2011 ABLE Biosciences is a CRO providing bioanalytical, analytical, biomarkers and proteomic services to customers as a key part of the drug and diagnostic development process.

Aldevron Freiburg GmbH

08 December 2011 Rapidly generate custom-made antibodies starting from cDNA (core technology), protein or peptide against a wide range of targets.

Allosterix Ltd

08 December 2011 Allosterix offers first in class, highly specific TACE\ ADAM17 inhibitor for the treatment of EGFR related cancers. Allosterix also offer a drug design service for the design of highly specific, drugable inhibitor for every enzyme.

Almetis

08 December 2011 Almetis designs and develops anticancer metal-based molecules targeting the cell metabolism.

AlphaSzenszor Inc.

08 December 2011 Nanotube based electronic sensors for early detection and diagnosis of cancer using biomarkers in human breath.

Argon Pharma

08 December 2011 ARGON PHARMA is a biotech company focused on the development of innovative therapies to combat cancer based in drug discovery of small molecules, and also in the development new technologies based on biodegradable polymers for drug delivery and diagnostic applications.

Astrid Research Kft

08 December 2011 Astrid is one of the largest, privately held bioinformatics companies in Europe with offices in Austria and Hungary. Our focus is data management and analysis for genomics research by providing comprehensive IT solutions for diagnostic marker and therapeutic target identification.

Biognos AB

08 December 2011 Biognos AB is focused on computational screening, both ligand-based (similarity searches) and structure-based (docking) using large databases of small molecules

BioMarCare Technologies Ltd.

08 December 2011 BioMarCare is a cancer diagnostics company developing blood and biopsy assays based on novel biomarker-panels for early detection, prognosis and monitoring of breast and colorectal malignancies.

Biomotif AB

08 December 2011 Biomotif technology for: Conformational Epitope Mapping, Binding Site/Mode-of-action studies and Compound-Fishing-Epitope Imprinting affinity capture in the liquid phase.

« BackNext »Page 1 of 3
08 Dec 2011